Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab dose comparison in infants with retinopathy of prematurity
2013-002539-13Phase 2Completed
- Sponsor
- University Hospital Freiburg
- Start
- Dec 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ranibizumab in retinopathy of prematurity (ROP) (2 arms), sponsored by University Hospital Freiburg. Primary endpoint: Number of infants without need for rescue treatment. Started Dec 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2013-002539-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002539-13.